Axonics raises FY23 revenue view to $362M from $358M, consensus $358.7M

Sees FY23: Sacral neuromodulation revenue of $288.5 million, an increase of 30% compared to fiscal year 2022. Bulkamid revenue of $73.5 million, an increase of 42% compared to fiscal year 2022.”